Meeting
2023 ASCO Annual Meeting
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
Authors
Lionel Falchero
Hôpitaux Nord-Ouest, Service de Pneumologie et Cancérologie Thoracique, Villefranche-Sur-Saone, France
Lionel Falchero , Florian Guisier , Marie Darrason , Arnaud Boyer , Charles Dayen , Sophie Cousin , Patrick Merle , Regine Lamy , Anne Madroszyk , Josiane Otto , Pascale Tomasini , Pascale Missy , Franck Morin , Virginie Westeel , Nicolas Girard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8583)
DOI
10.1200/JCO.2023.41.16_suppl.8583
Abstract #
8583
Poster Bd #
210
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Dares: A phase II trial of durvalumab and ablative radiation in extensive stage small cell lung cancer.
First Author: Aditya Juloori
Poster
2021 ASCO Annual Meeting
DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial.
First Author: Patrick M. Forde
Poster
2020 ASCO Virtual Scientific Program
A phase Ib/II study of niraparib plus temozolomide plus atezolizumab versus atezolizumab as maintenance therapy in extensive-stage small cell lung cancer (TRIO-US L-06).
First Author: Amy Lauren Cummings
Poster
2016 ASCO Annual Meeting
Second-line chemotherapy efficacy in patients with previously treated advanced thymic carcinoma: A retrospective analysis of 192 patients from NEJ023 Study.
First Author: Shunichiro Iwasawa